---
title: "Windward Bio Raises $251.2M in Nasdaq IPO and Private Placement"
description: "Swiss biotech company Windward Bio has raised approximately $251.2 million through an initial public offering and a concurrent private placement, according to a report from investing.com."
canonical_url: https://clinicalterminal.com/article/108991298
section: funding-and-ma
byline: Victoria Shi · AI Funding Reporter
date_published: 2026-11-18T15:27:04.015Z
date_label: November 18, 2026
image: https://firebasestorage.googleapis.com/v0/b/clinical-ai-design.firebasestorage.app/o/desk-heroes%2Ffe_D8CO5y22bkaQ3x7ceVVn%2Fhero_b2bf9c950208_w1920.jpg?alt=media
source: https://clinicalterminal.com
---

# Windward Bio Raises $251.2M in Nasdaq IPO and Private Placement

*Swiss biotech company [Windward Bio](https://app.clinicalterminal.com/company/108950473) has raised approximately $251.2 million through an initial public offering and a concurrent private placement, according to a report from investing.com.* [2]

The company began trading on the Nasdaq on Nov. 13, 2026, under the ticker symbol WWB, multiple outlets reported. The IPO consisted of 11,838,234 common shares priced at $17.00 per share, which included the full exercise of the underwriters' option to purchase additional shares, investing.com reported. Concurrently, Sanofi purchased $50 million in shares and pre-funded warrants in a private placement at the IPO price, according to reports from ThePharmaLetter and Endpoints News. [2, 4]

Windward Bio, headquartered in Basel, Switzerland, focuses on developing treatments for inflammatory respiratory and dermatological diseases, according to several reports. The company's lead drug candidate is WIN378, a long-acting TSLP inhibitor licensed from China's Kelun-Biotech, pharmaphorum.com reported. The drug is in a Phase 2/3 trial for severe uncontrolled asthma and a Phase 2 trial for chronic obstructive pulmonary disease, the report said. [3, 4]

The funds are intended to advance WIN378 into a second Phase 3 trial for asthma, Endpoints News reported. [5]

Windward Bio was launched in January 2025, according to ThePharmaLetter. Prior to the IPO, the company had raised $365 million in private funding, including a $200 million Series A round in January 2025 and a $165 million crossover financing in May 2026 led by OrbiMed, according to reports from ThePharmaLetter and multiples.vc. New investors in the May 2026 round included RA Capital Management, Janus Henderson Investors, Sanofi Ventures, and Harbour BioMed, according to BioSpace and Harbour BioMed. [4, 6]

[Luca Santarelli](https://app.clinicalterminal.com/person/108950073) is the founder, CEO and chairman of Windward Bio, according to his LinkedIn profile. Jefferies, TD Cowen, Piper Sandler, and UBS Investment Bank acted as joint book-running managers for the offering, investing.com reported. [1, 2]

## Sources

1. [LinkedIn post by Luca Santarelli](https://www.linkedin.com/posts/luca-santarelli-67886b8_windward-bio-rings-the-opening-bell-activity-7527095020760264704-7b0S) — Proud to have launched the IPO of Windward Bio!
2. [Investing.com](https://www.investing.com/news/stock-market-news/windward-bio-raises-2512m-in-ipo-on-nasdaq-432SI-5030848) — Windward Bio raises $251.2M in IPO on Nasdaq By Investing.com
3. [pharmaphorum](https://pharmaphorum.com/news/windward-bio-catches-175m-its-ipo) — Windward Bio catches $175m from its IPO
4. [thepharmaletter.com](https://www.thepharmaletter.com/ones-to-watch/windward-bio) — Windward Bio
5. [Endpoints News](https://endpoints.news/windward-bio-hits-nasdaq-with-175m-ipo-plus-another-50m-from-sanofi/) — Windward Bio hits Nasdaq with $175M IPO, plus another $50M from Sanofi
6. [BioSpace](https://www.biospace.com/press-releases/windward-bio-announces-165m-crossover-financing-to-advance-pipeline-of-long-acting-immunology-therapies-with-best-in-disease-potential) — Windward Bio Announces $165M Crossover Financing to Advance Pipeline of Long-Acting Immunology Therapies With Best-in-Disease Potential, 2026-05-04

---
Canonical article: https://clinicalterminal.com/article/108991298  
Entity profiles referenced above resolve to https://app.clinicalterminal.com.
